.png){kind=icon}
返回
Mammalian Target of Rapamycin Inhibitor Levels Decrease Under Cenobamate Treatment
.png){kind=icon}
PRE
AI
DOI：10.1016/j.pediatrneurol.2024.08.009.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Background: Everolimus therapy has been approved in Tuberous Sclerosis Complex (TSC), for drug- resistant epilepsy as adjunctive therapy. A novel anti-seizure medication is cenobamate, which was approved for adults as adjunctive treatment for focal-onset seizures in drug-resistant epilepsy and is now commonly used in patients with TSC. Drug-drug interactions between cenobamate and mammalian target of rapamycin (mTORi) have not been prospectively evaluated, even though these agents are frequently administered together. Methods: We performed a retrospective analysis of patients with TSC and compared mTORi drug levels before and after treatment initiation with cenobamate. Results: We evaluated 20 patients with clinically diagnosed TSC (male: 55%, female: 45%) with a median current age at last visit of 17.0 years (range: 4-41 years, interquartile range [IQR]: 12.5 years). All patients received mTORi treatment of either everolimus (N = 12, 60%) or sirolimus (N = 8, 40%). Cenobamate treatment led to seizure freedom in 2 patients (10%), reduction of seizures in 9 patients (45%) and no change in seizure frequency in 9 patients (45%). Median maximal cenobamate dose was 200 mg (range: 100-500 mg, IQR: 262.5 mg), for example, 3.2 mg/kg/day (range: 0.8-9.5 mg/kg/day, IQR: 3.2 mg/kg/day). Median everolimus levels decreased significantly after cenobamate initiation from 5.1 ng/ml (range: 1.9-11.6 ng/ml, IQR: 3.8 ng/ml) to 3.4 ng/ml (range: 1-7.9 ng/ml, IQR: 1.7 ng/ml, P = 0.01221). The median sirolimus level did not decrease significantly (P = 0.3828). Conclusion: Everolimus levels decreased following cenobamate initiation. This is likely due to CYP3A4 induction of cenobamate. We recommend monitoring of serum plasma levels of mTORi co-administered with cenobamate and adjustment of mTORi doses accordingly.
Keyword:
mTOR inhibitor
Everolimus
Sirolimus
Cenobamate
Tuberous sclerosis complex
期刊
IF:
2.1
论文数:
6.1K
被引数:
7.0K
机构
引用论文
Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex鉴别mTOR抑制剂依维莫司和西罗莫司在结节性硬化症中的作用.png)
NEURO-ONCOLOGY
OAAI
NEURO-ONCOLOGYIF13.4
OAAI分享收藏Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialLANCET
LANCETIF88.5
PREAI
分享收藏Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations更新国际结节性硬化症诊断标准及监测和管理建议PEDIATRIC NEUROLOGYOAAI
PEDIATRIC NEUROLOGYIF2.1
OAAI分享收藏Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and TolerabilityCNS DRUGS
CNS DRUGSIF7.4
PREAI
分享收藏A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazamEPILEPSIAOAAI
EPILEPSIAIF6.6
OAAI分享收藏 没有更多内容
没有更多内容